Mirum Pharmaceuticals (MIRM) Return on Sales (2021 - 2026)

Mirum Pharmaceuticals' Return on Sales history runs 6 years deep, the most recent figure standing at 0.05% for Q1 2026.

• On a quarterly basis, Return on Sales fell 5.0% year-over-year to 0.05% in Q1 2026; TTM through Mar 2026 was 0.01%, a 1.0% decrease from a year earlier, with the FY2025 full-year figure at 0.0%, changed 0.0% from the prior year.
• Return on Sales eased to 0.05% in Q1 2026 per MIRM's latest filing, from 0.0% in the prior quarter.
• Across five years, Return on Sales topped out at 0.0% in Q3 2025 and bottomed at 0.05% in Q1 2026.
• The 5-year median for Return on Sales is 0.0% (2023), against an average of 0.01%.
• Biggest YoY gain for Return on Sales was 8 bps in 2022; the steepest drop was 20 bps in 2022.
• Year by year, Return on Sales stood at 0.01% in 2022, then soared by 61 bps to 0.01% in 2023, then soared by 53 bps to 0.0% in 2024, then jumped by 84 bps to 0.0% in 2025, then slumped by 12745 bps to 0.05% in 2026.
• Per Business Quant, the three latest MIRM Return on Sales figures stand at 0.05% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025).